Pan et al. (2019), phase I/II clinical trial, showed that the total number of transplanted cells, patient’s age, blood fibrinogen, arterial occlusion level, and TcPO2 directly affected the outcome of PB-CD34+ MNCs therapeutic angiogenesis for no-option CLI cases (Pan et al., 2019). Moreover, the different observations identified suitable outcomes of the PB-CD34+ MNC therapy in CLI patients with atherosclerotic peripheral arterial disease and Buerger’s disease (Supplementary Table S1). Here, CD34 is linked to peripheral arterial disease.